- Home
- HIT vs RPTX Comparison
HIT vs RPTX Comparison
Compare HIT & RPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HIT
- RPTX
- Stock Information
- Founded
- HIT 1964
- RPTX 2016
- Country
- HIT United States
- RPTX Canada
- Employees
- HIT N/A
- RPTX N/A
- Industry
- HIT Specialty Insurers
- RPTX Biotechnology: Pharmaceutical Preparations
- Sector
- HIT Finance
- RPTX Health Care
- Exchange
- HIT Nasdaq
- RPTX Nasdaq
- Market Cap
- HIT 37.2M
- RPTX 38.3M
- IPO Year
- HIT 2024
- RPTX 2020
- Fundamental
- Price
- HIT $0.72
- RPTX $1.31
- Analyst Decision
- HIT
- RPTX Strong Buy
- Analyst Count
- HIT 0
- RPTX 3
- Target Price
- HIT N/A
- RPTX $4.50
- AVG Volume (30 Days)
- HIT 707.6K
- RPTX 369.2K
- Earning Date
- HIT 04-14-2025
- RPTX 05-13-2025
- Dividend Yield
- HIT N/A
- RPTX N/A
- EPS Growth
- HIT N/A
- RPTX N/A
- EPS
- HIT 0.02
- RPTX N/A
- Revenue
- HIT $22,380,959.00
- RPTX $1,073,000.00
- Revenue This Year
- HIT $58.79
- RPTX N/A
- Revenue Next Year
- HIT N/A
- RPTX N/A
- P/E Ratio
- HIT $48.91
- RPTX N/A
- Revenue Growth
- HIT 11.24
- RPTX N/A
- 52 Week Low
- HIT $0.51
- RPTX $0.89
- 52 Week High
- HIT $7.59
- RPTX $4.29
- Technical
- Relative Strength Index (RSI)
- HIT N/A
- RPTX 52.14
- Support Level
- HIT N/A
- RPTX $1.33
- Resistance Level
- HIT N/A
- RPTX $1.45
- Average True Range (ATR)
- HIT 0.00
- RPTX 0.09
- MACD
- HIT 0.00
- RPTX -0.01
- Stochastic Oscillator
- HIT 0.00
- RPTX 28.57
About HIT Health In Tech Inc. Class A Common Stock
Health In Tech Inc is an insurance technology platform company. It offers a marketplace that processes in the healthcare industry through vertical integration, process simplification, and automation. The group removed friction and complexities, it streamlined the underwriting, sales, and service process for insurance companies, licensed brokers, and TPAs.
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.